Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Kazia Therapeutics doses first patient in paediatric brain cancer trial

Kazia Therapeutics initiated dosing in its PNOC035 clinical study evaluating drug candidate paxalisib alongside gemcitabine for children and young adults with recurrent AT RT brain cancer

We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.

Read the original at vir.com.vn →

More in Health & Medicine

More from Friday 11 September →